• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

Valeant Names Perrigo's Joseph Papa Chairman and CEO; Shares Jump

Valeant delighted shareholders Monday with news that Perrigo's Joseph Papa is getting into the driver's seat. 
By JAMES PASSERI Apr 25, 2016 | 10:40 AM EDT
Stocks quotes in this article: VRX, PRGO, MYL

Valeant Pharmaceuticals's (VRX) much-needed management reshuffle is beginning to take shape with Monday's announcement that Joseph Papa will be replacing Michael Pearson as chairman and CEO, and shareholders seem to love it.

Shares of Valeant -- whose subsidiaries include eyecare giant Bausch & Lomb and skincare maker CeraVe -- jumped 4% in opening trading Monday after the company confirmed last week's rumors that Papa, who had been the CEO of Big Pharma rival Perrigo (PRGO) since 2006, will be taking the helm of Valeant in early May.

"Valeant has world-class franchises, important treatments for patients across numerous therapeutic areas and a very talented and dynamic workforce, and I am confident that the company has a bright future ahead," Papa said in statement Monday. He also noted Valeant will refocus its efforts on "operating with integrity" and will be providing customers with "safe and affordable products."

Shareholders appear hopeful that Papa's new direction will help the struggling Canadian drugmaker reverse a persistent decline in share prices over the past seven months.

Valeant shares are down 65% so far in 2016, as Congress and the SEC continue to probe the company's bookkeeping and drug-pricing practices. The company's departing CEO, Michael Pearson, is scheduled to testify in front of the Senate Special Committee on Aging on Wednesday.

Allegations of "gouging" patients through "predatory pricing" have gathered significant attention in the media over the past several months, with such charges most notably appearing in the rhetoric of Democratic presidential candidate Hillary Clinton's campaign.

Valeant has also so far admitted to at least $58 million of improperly booked revenue tied to its former partnership with mail-order pharmacy Philidor, which has led to the delay of its annual 10-K filing with the SEC. The delay has led to an ongoing standoff with creditors over violations of Valeant's debt covenants.

Shareholders are hoping that the appointment of the new CEO will draw a line under these problems and that he will bring new strategies to engineer a sustainable recovery. Papa's track record means their hopes have high chances of being fulfilled.

He developed a shrewd eye for mergers and acquisitions in the Big Pharma scene throughout his tenure at Perrigo -- especially with the $6.7 billion acquisition of Irish rival Elan in 2013 -- which has helped drive his former company's shares up roughly 900% since 2006, BMO Capital analyst Alex Arfaei said in a Friday investment note.

Papa, who helped grow Perrigo into a pharmaceutical giant with a more than $17 billion market cap, is also known for his defensive plays on the M&A front, most notably in helping to dodge a $26 billion hostile takeover bid by Mylan last November.

He will be replaced at the helm of Dublin-based drugmaker Perrigo by John Hendrickson, who has been the company's president since October, after serving as vice president of Perrigo's global supply chain from 2006-2015.

"He has made exceptional contributions to the business during his 27 year tenure, including leading our U.S. Consumer Healthcare business, and we are confident that he has the industry expertise and the operational track record to continue to drive growth," Perrigo chairman Laurie Brlas said in a statement Monday.

Valeant's management reshuffle has also included the addition of billionaire activist Bill Ackman -- whose hedge fund, Pershing Square, holds a 9% stake in Valeant. Stephen Fraidin, Pershing's vice chairman, was also named to the board of directors last month.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from owning individual securities.

TAGS: Investing | U.S. Equity | Healthcare

More from Healthcare

I'm Buying Arcturus Therapeutics Stock and Here's the Reason Why

Jim Collins
Apr 5, 2021 10:15 AM EDT

My COVID vaccine eligibility actually began about a week before my symptoms began.

Gilead Sciences Quant Upgrade Got Me Thinking

Bruce Kamich
Mar 31, 2021 1:55 PM EDT

The upgrade got my attention, but positive-looking charts pushed me over the edge.

Jim Cramer: For This Pandemic, and the Next, There Are Several Stocks I Like Now

Jim Cramer
Mar 31, 2021 7:01 AM EDT

There's an undercurrent that will grow over time, basically what tailwinds from the pandemic will stay with us after the pandemic's over.

The Doctor Found Something Amiss on the Charts of Teladoc

Bruce Kamich
Mar 30, 2021 2:27 PM EDT

The name appears bearish and risky right now.

Here's Why I'm Avoiding AstraZeneca Stock

Jim Collins
Mar 25, 2021 10:00 AM EDT

The AZN affair exposes the seedy underbelly of drug manufacturing, and the COVID-19 vaccine is certainly a drug.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 04:44 PM EDT PAUL PRICE

    Pretty Incredible + Hard to Believe

  • 11:18 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    The 5 Pillars of Exceptional Trading
  • 08:05 AM EDT BOB LANG

    Bitcoin vs. Gold: Which Should You Invest In Now?

    Read my article TheStreet here!
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login